Needham Maintains Buy on NewAmsterdam Pharma Co, Lowers Price Target to $40
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and lowers the price target from $42 to $40.
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and lowers the price target from $42 to $40.